• Currency:
0

Ipamorelin 5mg

£21.00
  • Ex Tax:£17.50
  • Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3]  It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4]

    Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals and humans.[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactinfollicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone(GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.930

    Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus.[6][7]

    Source: Wikipedia

    InChI Key:

    NEHWBYHLYZGBNO-BVEPWEIPSA-N

    Molecular Formula:C38H49N9O5
    UNII:

    Y9M3S784Z6

    Chemical Names:

    Ipamorelin

    170851-70-4

    C38H49N9O5

    CHEMBL58547

    SCHEMBL183305

    More...
    Molecular Weight:

    711.868 g/mol

    SourcePubChem

    Clinical Trials:

    Ipamorelin has been investigated for the treatment of Ileus:

    CTIDTitlePhaseStatusDate
    NCT00672074Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus2Completed2017-04-12
    NCT01280344Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function2Completed2017-04-12

    SourcePubChem

    Usage: 

    Product is prepared for LABORATORY RESEARCH USE ONLY. The product may not be used for other purposes.

    References:

    1.  Gobburu, Jogarao V. S.; Agersø, Henrik; Jusko, William J.; Ynddal, Lars (1999). "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers". Pharmaceutical Research16 (9): 1412–1416. doi:10.1023/A:1018955126402ISSN 0724-8741.
    2. ^ Moulin, Aline; Ryan, Joanne; Martinez, Jean; Fehrentz, Jean-Alain (2007). "Recent Developments in Ghrelin Receptor Ligands". ChemMedChem2 (9): 1242–1259. doi:10.1002/cmdc.200700015ISSN 1860-7179PMID 17520591.
    3. Jump up to:a b c d Raun, K; Hansen, B.; Johansen, N.; Thogersen, H; Madsen, K; Ankersen, M; Andersen, P. (1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology139 (5): 552–561. doi:10.1530/eje.0.1390552ISSN 0804-4643.
    4. ^ Isidro, Maria; Cordido, Fernando (2006). "Growth Hormone Secretagogues". Combinatorial Chemistry & High Throughput Screening9 (3): 175–180. doi:10.2174/138620706776055458ISSN 1386-2073.
    5. Jump up to:a b Estrada, R. Cañete; Jiménez-Reina, L.; de la Torre, M.J.; Bernal, J. (2002). "Chronic In Vivo Ipamorelin Treatment Stimulates Body Weight Gain and Growth Hormone (GH) Release In Vitro in Young Female Rats"6 (1): 37–46. ISSN 1136-4890.
    6. ^ Beck, David E.; Sweeney, W. Brian; McCarter, Martin D. (2014). "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients". International Journal of Colorectal Disease29 (12): 1527–1534. doi:10.1007/s00384-014-2030-8ISSN 0179-1958.
    7. ^ AdisInsight. "Ipamorelin". Retrieved 10 June 2015.


    Wikipedia text is published under the Creative Commons Attribution Share-Alike licence (CC-BY-SA) and is re-distributed here under that licence. Licensing information can be found at http://creativecommons.org/licenses/by-sa/3.0


    Write a review

    Please login or register to review